Microfluidic Single-Cell Trapping for Non-Invasive Diagnostics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-invasive prenatal testing (NIPT) and oncological diagnostic methods suffer from high false positive rates due to low fetal cell-free DNA concentrations and difficulties in isolating and analyzing single cells, limiting their predictive value and accuracy.
Innovation Solution
A method involving the enrichment of fetal or cancer cells from a blood sample using techniques like immunomagnetic separation and microfluidic manipulation, followed by cell trapping, lysis, and nucleic acid amplification, allowing for low-depth sequencing and determination of cell provenance to provide accurate diagnostic readouts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cell-free DNA sequencing is used for non-invasive prenatal testing, then the test can be performed non-invasively, but the positive predictive value remains low due to high false positive rates
Solution Approach 1:
The patent extracts and isolates individual fetal cells from maternal blood using microfluidic devices, separating the target analyte (fetal cell) from the background (maternal cells). This extraction enables direct genomic analysis of fetal cells without relying on low-concentration fetal cell-free DNA, thereby improving positive predictive value while maintaining non-invasive sampling
Solution Approach 2:
The patent introduces microfluidic trapping devices as an intermediary between blood sampling and genomic analysis. These devices enable single-cell isolation and lysis, serving as a bridge that transforms the low-concentration fetal cell-free DNA approach into a direct fetal cell genomic analysis approach, resolving the contradiction between non-invasive operation and diagnostic reliability
2Quantity of substance
If fetal cells are isolated using conventional methods, then cell enrichment can be achieved, but fetal cell purity remains below 10% due to variable recovery and low concentration
Solution Approach 1:
The patent replaces conventional mechanical isolation methods (posts in microfluidic channels, macro scale immunomagnetic separation, size-based ISET) with a novel microfluidic trapping approach using junctions and constrictions. This substitution achieves superior fetal cell purity by exploiting the unique ability to trap and isolate individual rare fetal cells from large volumes of maternal blood, overcoming the limitations of bulk enrichment methods
Solution Approach 2:
The patent changes the physical parameters of the isolation system by using microfluidic channel geometries with specific junction designs and flow conditions. By controlling flow rate, pressure, and channel dimensions, the system achieves high-purity fetal cell isolation through parameter optimization rather than relying on cellular properties alone, thereby achieving purity above 10%
3Measurement precision
If single cell isolation is performed using limiting dilution, then single cells can be obtained, but only about 60% of wells contain a single cell due to distribution variability
Solution Approach 1:
The patent replaces the statistical limiting dilution method with a deterministic microfluidic trapping system. The microfluidic device uses physical junctions and constrictions to deterministically trap and isolate individual cells, eliminating the random distribution variability inherent in limiting dilution. This substitution increases the isolation success rate from 60% to near 100% by ensuring each trap contains at most one cell
Solution Approach 2:
The patent introduces microfluidic trapping structures as an intermediary between cell suspension and analysis. These structures provide deterministic single-cell isolation through controlled fluid dynamics, serving as a mediator that guarantees single-cell occupancy in each trap, thereby resolving the contradiction between measurement precision and productivity
4Measurement precision
If high-depth sequencing is used to determine fetal trisomy, then copy number accuracy can be achieved, but sequencing costs increase and data spread exceeds 5%
Solution Approach 1:
The patent extracts and analyzes genomic material from individual fetal cells directly, rather than analyzing bulk fetal cell-free DNA. This extraction enables lower-depth sequencing because the genomic material comes from pure fetal cells without maternal contamination, reducing the need for high-depth sequencing to achieve accurate copy number determination, thereby decreasing sequencing costs and data complexity
Solution Approach 2:
The patent introduces single-cell lysis and direct genomic analysis as an intermediary step between cell isolation and sequencing. This intermediary process concentrates fetal genomic material from individual cells, enabling accurate copy number determination at lower sequencing depths compared to bulk cfDNA analysis, thus resolving the contradiction between measurement precision and energy loss
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces false positives and increases the positive predictive value of diagnostic tests, enabling highly accurate non-invasive prenatal testing and oncological diagnostics with lower sequencing costs.
Implementation Method 1
The sub-population can be fetal cells for NIPT usage, or cancer cells for oncological testing. The enrichment process may employ a variety of techniques including immunomagnetic separation
Implementation Method 2
A number of different approaches for isolating and analyzing single cells using microfluidic devices have also been proposed. Cells are then trapped at channel junctions
Implementation Method 3
followed by cell trapping, lysis, and nucleic acid amplification
Data Source
AI summary
The invention discloses diagnostic techniques based on single cell genomics, consisting of obtaining a blood sample, enriching a sub-population of cells present in the blood sample, sequestering individual cells or group of cells from the blood sample, obtaining sequencing data from the sequestered cells or group of cells, using genetic variant information to determine the provenance of the cells, and genetically analyzing the cells of the correct provenance to provide a diagnostic readout. Using the cell-based testing techniques of the invention, the number of false positives is greatly reduced when compared to cell-free DNA (cfDNA) based traditional testing techniques. The invention may be effectively employed for non-invasive prenatal (NIPT) diagnostics, oncological testing and other diagnostic procedures.